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Abstract
Background: The pathologies of numerous retinal degenerative diseases can be attributed to a multitude of genetic factors,
and individualized treatment options for afflicted patients are limited and cost-inefficient. In light of the shared
neurodegenerative phenotype among these disorders, a safe and broad-based neuroprotective approach would be
desirable to overcome these obstacles. As a result, gene delivery of secretable-neuroprotective factors to Mu¨ller cells, a type
of retinal glia that contacts all classes of retinal neurons, represents an ideal approach to mediate protection of the entire
retina through a simple and innocuous intraocular, or intravitreal, injection of an efficient vehicle such as an adeno-
associated viral vector (AAV). Although several naturally occurring AAV variants have been isolated with a variety of
tropisms, or cellular specificities, these vectors inefficiently infect Mu¨ller cells via intravitreal injection.
Methodology/Principal Findings: We have previously applied directed evolution to create several novel AAV variants
capable of efficient infection of both rat and human astrocytes through iterative selection of a panel of highly diverse AAV
libraries. Here, in vivo and in vitro characterization of these isolated variants identifies a previously unreported AAV variant
ShH10, closely related to AAV serotype 6 (AAV6), capable of efficient, selective Mu¨ller cell infection through intravitreal
injection. Importantly, this new variant shows significantly improved transduction relative to AAV2 (.60%) and AAV6.
Conclusions/Significance: Our findings demonstrate that AAV is a highly versatile vector capable of powerful shifts in
tropism from minor sequence changes. This isolated variant represents a new therapeutic vector to treat retinal
degenerative diseases through secretion of neuroprotective factors from Mu¨ller cells as well as provides new opportunities
to study their biological functions in the retina.
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Introduction
As a therapeutic device, adeno-associated viral (AAV) mediated
ocular gene therapy holds tremendous promise for treating and
potentially curing a variety of inherited retinal degenerative
diseases, such as glaucoma, age-related macular degeneration
(AMD), retinitis pigmentosa, and other blinding diseases. The
therapeutic potential of AAV-mediated gene delivery to the retina
has best been illustrated by the positive results from three phase I
clinical trials for Leber’s Congenital Amaurosis (LCA), a rare
autosomal recessive blinding disease caused by loss of function
mutations in the visual cycle enzyme retinol isomerase (RPE65)
required to synthesize 11-cis retinal [1–3]. Gene-replacement
therapy employing an AAV vector (rAAV) bearing a functional
copy of the RPE65 gene in patients afflicted with the null mutant
RPE65 resulted in significant improvements in visual function with
no observable toxicity. These clinical trials clearly lay the
foundation for AAV in retinal gene therapy, providing the first
example of successful gene therapy with long-term safety and
amelioration in visual function. Moreover, these results set the
stage for the application of AAV-mediated gene delivery towards
other retinal degenerative diseases.
Importantly, genetic heterogeneity is a key feature of retinal
degeneration conditions, and to date, over 130 genes with
mutations causing one or more forms of inherited orphan retinal
degenerative diseases have been cloned, and over 50 more have
been identified based on candidate gene studies or linkage
mapping (http://www.sph.uth.tmc.edu/retnet). This large genetic
heterogeneity, leading to a common phenotype of photoreceptor
cell death, suggests that a mutation-independent neuroprotective
strategy may be the most practical solution to a clinical treatment.
Therefore, there is a strong need for a simple, safe, and broad-
based ocular gene delivery strategy that provides sustained
production of a neuroprotective or anti-angiogenic therapeutic
for these conditions.
Several viral vector systems have been evaluated for ocular gene
delivery; however, AAV offers distinct advantages in safety,
stability, and efficiency. AAV belongs to the Parvoviridae family
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and Dependovirus genus, whose members require co-infection
with a helper virus such as adenovirus to promote replication, and
AAV establishes a latent infection in the absence of a helper [4].
Virions are composed of a 25 nm icosahedral capsid encompass-
ing a 4.9 kb single-stranded DNA genome [5] with two open
reading frames: rep and cap. The non-structural rep gene encodes
four regulatory proteins essential for viral replication, whereas cap
encodes three structural proteins (VP1–3) that assemble into a 60-
mer capsid shell. This viral capsid mediates the ability of AAV
vectors to overcome many of the biological barriers of viral
transduction–including cell surface receptor binding, endocytosis,
intracellular trafficking, and unpackaging in the nucleus [6–8]. In
addition, the capsid diversity found among natural AAV variants,
or serotypes, isolated from human and nonhuman primate tissues
accounts for its diverse tropisms, as AAV has been shown in
animal models to deliver genes to cells in numerous tissues
including the retina, brain, muscle, and lung [9–12]. As some
AAV serotypes bind to glycans for receptor-mediated cellular
entry, this variety is in part based on the varying glycan
dependences found among AAV serotypes. AAV2 shows strong
dependence on heparan sulfate proteoglycans (HSPG) for
transduction, whereas AAV1, 5, and 6 are dependent on N-linked
sialic acids [4,5,13].
Subretinal administration of many of these AAV variants has
led to efficient gene expression in a number of retinal neurons and
epithelia, including photoreceptors and RPE [14,15], and it is thus
the injection route employed by current clinical therapies to
achieve sufficient transduction for rescue [2]. However, this
surgical approach requires creating a retinotomy (a hole through
the neurosensory retina) and mechanically detaching the photo-
receptor layer from its underlying supportive epithelium (RPE)
through injection of an AAV fluid suspension, generating a ‘‘bleb’’.
The resulting retinal detachment has had documented damaging
effects, triggering cellular stress response pathways, reactive gliosis,
retinal disorganization, photoreceptor degeneration, and function-
al losses in vision [16,17]. In retinas compromised by degenera-
tion, the effects of this detachment would only be further
magnified [18]. Additionally, as degeneration occurs throughout
the retina in most retinal diseases, use of a focal delivery and
treatment strategy via subretinal injection into a specific region is
not optimal because only cells within the ‘‘bleb’’ are transduced
[19–21]. An intravitreal injection technique, whereby virus is
administered directly into the vitreous of the eye, presents a more
innocuous and simple approach for gene delivery to the retina,
and it allows for a broader area of retinal transduction since the
vitreous contacts the entire underlying retinal surface. Intravitreal
injection is already routinely used clinically to administer anti-
vascular endothelial growth factor (anti-VEGF) antibody for the
treatment of AMD [22].
Despite these benefits, intravitreal injections pose significant
challenges. First, dilution of vector into the vitreal fluid leads to
lower vector concentrations compared to subretinal injections, a
particular concern for larger mammals. However, intravitreal
vector administration into macaque eyes showed that AAV is still
able to overcome this challenge and lead to retinal transduction
[23]. An additional consideration is that the increase in vitreous
viscosity in humans above the age of 40 could impair the diffusion
of the virus in older patients’ vitreous, though this concern is
potentially offset by an increase in liquid vitreous localized directly
in front of the retina [24] enabling one to inject into this fluid
region and avoid the more viscous vitreous gel. In addition to these
vitreal fluid barriers, treating photoreceptor degeneration in early
stages of disease progression using gene delivered neurotrophic
factors requires high efficiency vectors, but intravitreal injection of
conventional AAV serotypes cannot mediate sufficient expression
of these factors in proximity to the photoreceptors undergoing
degeneration in the outer nuclear layer of the retina to achieve
effective rescue of retinal function [25]. Infecting Mu¨ller glia, a cell
that is accessible from the vitreous and transverses the entire
thickness of the retina, would be ideal to mediate expression of
secreted neurotrophic or anti-angiogenic factors throughout all
layers of the retina (Fig. 1).
Mu¨ller cells serve numerous, significant physiological functions
in the retina including but not limited to: metabolic support of
neurons, K+ and water homeostasis, free radical scavenging and
oxidative protection, neurotrophic secretion, and neurotransmitter
and retinoid uptake and recycling [26]. They are thus in many
ways analogous to astrocytes in the central nervous system (CNS),
sharing many of the same cellular properties [27,28]. Moreover,
because Mu¨ller cells can survive under neurodegenerative
conditions, they may mediate independent protection of the entire
retina for a more extended period compared to a transduced
damaged or dying neuron impacted by one of these diseases. As
such, they represent an ideal candidate for viral gene therapy for
secretion of neuroprotective factors.
Recently, the efficiency of this approach has been demonstrated
as Mu¨ller cell secretion of neurotrophin-4 (NT-4) was shown to
protect photoreceptors from oxidative stress in a mouse model of
neovascularization through intravitreal injection [29]. However,
the therapeutic effect of this approach can be enhanced using a
more efficient AAV variant, as current AAV serotypes are limited
in their efficiency and specificity for intravitreal Mu¨ller transduc-
tion [25,29]. An AAV variant with greater Mu¨ller cell specificity
would also allow the use of fewer viral particles to achieve the
desired levels of expression and reduce the potential for ectopic
transfection, important considerations to minimize the immune
response to capsid proteins [15,30].
Recently, we applied directed evolution to select variants from
combinatorial libraries that demonstrate a diverse range of cellular
tropisms in vitro and in vivo relative to their parent serotypes as well
as variants with enhanced permissivity to astrocytes in vivo through
selection in primary human astrocytes [14,31]. Here, we further
explore the utility of these astrocyte-permissive variants for
intravitreal administration in the retina and identify a new AAV
variant with enhanced and specific intravitreal Mu¨ller cell
transduction in vivo. Efficient and specific intravitreal transduction
of Mu¨ller cells by this vector will permit the development of more
innocuous and effective treatments for retinal degenerative
conditions through panretinal secretion of neuroprotective or
anti-angiogenic factors, as well as new approaches to investigate
fundamental questions in the biological role of this cell type in the
retina.
Results
In vivo characterization of Mu¨ller cell permissive variants
We recently evolved several novel AAV capsids that efficiently
transduced both primary human astrocytes in vitro and rat
astrocytes in vivo using highly diverse AAV libraries (.107) [14].
These variants were generated via multiple evolutionary rounds
(i.e. diversification followed by positive selection for enhanced
astrocyte transduction in vitro) with several distinct libraries: (1) an
AAV2 random mutagenesis library generated via error prone
PCR [32], (2) a random chimera AAV library generated by
shuffling the cap genes of 7 natural human and non-human AAV
serotypes [31], and (3) a novel AAV2 library with surface-exposed
loops of the capsid library diversified based on a bioinformatics
approach [14].
Mu¨ller-Permissive AAV Variant
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Due to the shared properties between astrocytes and Mu¨ller cells,
we decided to explore the utility of these variants for intravitreal
transduction of Mu¨ller cells. Here, the eight isolated mutants that
demonstrated the greatest in vitro astrocyte infectivity (Fig. S1, [14])
were individually analyzed for the ability to transduce the retina from
the vitreous using double-stranded (ds) AAV CAG-GFP vectors
purified via iodixanol gradient ultracentrifugation and heparin
affinity chromatography. Intravitreal injections of 2.561010 genomic
particles revealed one previously unreported variant named ShH10,
derived from an AAV6 parent serotype from the shuffled (ShH)
library, that showed a dramatic increase in specificity and efficiency
for Mu¨ller cells relative to controls at three weeks post-injection
(Figs. 2, 3). Interestingly, no other mutants demonstrated visible
expression as determined by GFP fundus imaging and immunohis-
tochemistry (data not shown). Recombinant ShH10 (rShH10) led to
diffuse expression throughout the retina with a highly specific
transduction profile of approximately 94% Mu¨ller cells, 2%
interneurons, and 4% retinal ganglion cells (Figs. 2, 3, 4). In
comparison, the parent vector, AAV6, showed very low transduction
of the retina, and the related AAV2 vector showed a less specific
retinal tropism with a transduction profile of approximately 76%
Mu¨ller cells, 3% interneurons, and 21% retinal ganglion cells
(Figs. 2, 3, 4). Quantification of transduction efficiencies revealed
that ShH10 was approximately 62% more efficient at infecting
Mu¨ller cells relative to AAV2, infecting 22% vs. 14% of total Mu¨ller
cells respectively in transverse retinal slices (Fig. 3b).
Figure 1. Mu¨ller glia in the retina. Illustration of Mu¨ller glia spanning the entire retina, where they ensheath all neuronal types from retinal
ganglion cells (RGC) (bottom) to the photoreceptors. Modified from Histology of the Human Eye, an Atlas and Textbook. Hogan, Michael J., Jorge A.
Alvarado, Joan Esperson Weddell. Philadelphia: W. B. Saunders, 1971.
doi:10.1371/journal.pone.0007467.g001
Mu¨ller-Permissive AAV Variant
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Temporal observation of ShH10 expression using fundus
imaging, coupled with anti-laminin immunostaining of retinal
flatmounts to visualize vasculature, also revealed a unique tropism
for retinal astrocytes at earlier time points following injection
(Fig. 5). Unlike Mu¨ller cells, retinal astrocytes are not derived
from the retinal neuroepithelium, but serve some analogous roles
in the retina including providing nutritional support to neurons,
neurotransmitter metabolism, and ionic homeostasis [33]. They
also serve as axonal glial sheaths for ganglion cells bodies and
envelop the retinal vasculature, forming part of the blood-brain
barrier. One week post-injection, fundus imaging revealed
localized expression near those areas dense in retinal astrocytes,
e.g. the optic nerve and along retinal vasculature (Fig. 5a).
Additionally, transverse retinal sections showed that areas
underlying major vasculature bore strong Mu¨ller expression
(Fig. 5d). At later time points (2–3 weeks), expression became
more evenly spread, but interestingly, those regions in proximity to
vasculature ultimately maintained the strongest Mu¨ller cell
expression (Fig. 4).
Mutational analysis of ShH10
ShH10 is highly Mu¨ller cell selective, while AAV6 yields no
detectable retinal expression upon intravitreal administration, yet
intriguingly ShH10 differs from AAV6 at only four residues:
Figure 2. rShH10 expression following intravitreal injection in the adult rat retina. Confocal imaging of immunostained transverse retinal
sections 3 weeks post-injection of 2.561010 viral particles (vector genomes) of dsCAG-GFP vectors with capsids from AAV2 (A–C), ShH10 (D–F), and
AAV6 (G–I) (n = 6). Glutamine synthetase (GS) staining (red) (B,E,H) and visualization of colocalization (C,F,I) reveals more robust Mu¨ller cell expression
by ShH10 (E, F) relative to AAV2 (B,C), whereas AAV6 shows no visible expression (G–I). Additionally, GFP expression shows specific transduction of
Mu¨ller cells by ShH10 (D) compared to AAV2 (A), which exhibits considerably more transduction of retinal ganglion cells and interneurons.
doi:10.1371/journal.pone.0007467.g002
Mu¨ller-Permissive AAV Variant
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I319V, N451D, D532N, and H642N (Fig. S1). To analyze the
contributions of each of these mutations to ShH10’s novel
phenotype, single point mutants and all potential double mutants
were generated from the AAV6 cap gene via site-directed
mutagenesis. Each resulting variant was used to package rAAV-
CMV-GFP and was purified via iodixanol gradient ultracentrifu-
gation. To characterize the in vitro infectivity of these mutants, and
in particular their glycan dependence in light of the substantial
role proteoglycans and glycoproteins play in AAV transduction
[4,5,13], we analyzed their relative transduction efficiencies on a
panel of cell types: Pro5, a Pro5 mutant (Lec1) deficient in N-
linked sialic acid, CHO, and a CHO derivative (pgsA) deficient in
all glycosaminoglycans [34]. AAV6 exhibited a dependence on N-
linked sialic acids for efficient transduction, as previous studies
have indicated (Fig. 6c) [13] . However, the N451D mutation
decreased the viral dependence on N-linked sialic acids, and the
D532N mutation increased the viral transduction in the absence of
N-linked sialic acids (Fig. 6c). This D532N mutation, located near
the HSPG binding domain of the AAV6 capsid [35], may enable
the virus to utilize a transduction pathway distinct from AAV6
(Fig. 7).
Whereas AAV6 does not utilize HSPG for transduction
(Fig. 6b) [13] , several of the ShH10 mutations confer a new
dependence on HSPG. Intriguingly, AAV6 N451D exhibited
lower transduction levels relative to AAV6 in CHO cells, but when
coupled with the D532N mutation was more infective than either
AAV6 or AAV6 D532N (Fig. 6a). Comparing infection
efficiencies among the single point mutants between CHO and
pgsA cells, cell lines containing and lacking HSPG respectively,
AAV6 D532N was the only mutant to exhibit a substantial HSPG
dependence, which became more pronounced when coupled with
mutations I319V and N451D (Fig. 6b). The enhanced infectivity
of ShH10 is thus likely due to a synergy between mutations that in
part augments HSPG affinity as suggested by the heparin affinity
chromatogram (Fig. S2). To determine whether AAV6 mutations
that enhance infectivity also function in vivo, equal titer intravitreal
injections of 56109 genomic particles of recombinant vector
mutants carrying dsCAG-GFP revealed that that only AAV6
N451D was sufficient to confer the intravitreal Mu¨ller tropism.
This mutant was considerably more efficient than AAV6 on
Mu¨ller cells, though only half as efficient as ShH10 (Fig. 3, 7b).
Discussion
Our results demonstrate that the selection on primary human
astrocytes from our previous study [14] was sufficient to produce a
variant that overcomes intraocular barriers to infection, appar-
Figure 3. Transduction specificity and efficiency of ShH10.
Representative retinal slices from injected eyes were quantified for the
number of each cell type that was infected, as determined via GFP
expression, to generate histograms comparing tropism profiles (A) and
Mu¨ller transduction efficiencies (B) of rAAV2, rShH10, and rAAV6 dsCAG-
GFP. Transduction efficiencies were calculated based on the ratio of
Mu¨ller cells infected relative to the total number of Mu¨ller cells in a
10 mm transverse retinal slice (n = 6). Error bars represent standard
deviation among sample population.
doi:10.1371/journal.pone.0007467.g003
Figure 4. rShH10 expression in the whole retina following
intravitreal injection. Fluorescence microscopy of transverse retinal
sections from rShH10 dsCAG-GFP and rAAV6 dsCAG-GFP injected
animals 3 weeks post-injection reveals broadly spread expression by
ShH10 (B), with the most prominent expression localized at the
injection site. AAV6 (A) shows no visible expression.
doi:10.1371/journal.pone.0007467.g004
Mu¨ller-Permissive AAV Variant
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ently due to the cellular similarities between Mu¨ller glia and
astrocytes. These similarities may be based on their shared cellular
lineages, proteomic profiles, cellular polarity, and functionally
analogous roles in the CNS [26,27,36,37]. Interestingly, primary
astrocytes may have even been more suitable as a selection model
in vitro in lieu of directly selecting against primary Mu¨ller cells, as
proteomic profiling studies of primary Mu¨ller cells in culture
revealed a loss of cellular identity with significant shifts in
expression that suggested a dedifferentiation into a fibroblast-like
phenotype [38]. Characterizations of astrocytes in culture have
pointed to fewer changes, thus making this cell type relatively
closer to its initial in vivo state [39].
The in vitro evolution from our previous study selected for variants
with the capacity to bind to the glial cell surface and traffic to the
nucleus [14]. This may, in part, explain why the majority of variants
were unable to overcome the additional extracellular barriers
present in the retina in vivo [40]. However, one of the variants,
ShH10, showed strong expression following intravitreal injection.
Interestingly, sequence analysis (Fig. S1) reveals that ShH10 does
not share mutations with the other evolved variants except for
mutation H642N with variant ShH13, which has been shown in our
previous work to have an enhanced tropism for Mu¨ller cells upon
subretinal injection [14]. However, interestingly, ShH13 shows no
expression with intravitreal administration (data not shown).
Importantly, in beginning to mechanistically investigate viral
infection in the retina, our previous studies have shown that AAV
binding at the inner limiting membrane (ILM) is implicated in
mediating transduction via intravitreal injection of AAV serotype
2, and to a lesser extent 8 and 9 [40]. The ILM is a meshwork of
extracellular matrix proteoglycans located at the interface of the
vitreous and the retinal ganglion cell (RGC) layer and Mu¨ller cell
endfeet (Fig. 1), and it constitutes one of the first physical barriers
encountered by intravitreally injected virus. Receptors such as
HSPG and the 32 k laminin receptor that are abundant at this site
may allow binding of AAV serotypes 2, 8, and 9, whereas AAV
serotypes such as 1 and 5 that bind sialic acid, which is not found
at the ILM, show no expression in the rat retina following
intravitreal administration [15,25,40]. Once binding to the ILM
occurs, AAV then needs to overcome additional diffusional and
trafficking barriers in the retina to achieve efficient transduction.
In this respect, although AAV6 can infect cells upon subretinal
injection [14], its subretinal tropism is largely limited to retinal
pigment epithelia (RPE) and photoreceptors, and it completely
lacks the capacity to infect retinal cells upon intravitreal injection
(Fig. 2). These results suggest two distinct obstacles in AAV6’s
inability to infect Mu¨ller cells intravitreally: a marginal capacity to
first bind to the ILM via proteoglycan interactions and a limited
ability to then overcome Mu¨ller cell-surface and/or intracellular
barriers.
In first binding to the ILM, the presence of high levels of
heparan sulfate in the proteoglycan matrix of the ILM may
mediate viral accumulation at this site and act as a ‘sink’ [40].
Although this may sequester AAV particles, it may also effectively
localize the virus and prevent it from being cleared from the
vitreous via the trabecular meshwork, thereby facilitating subse-
quent transduction [41]. Although wild-type AAV6 does not
depend on HSPG for infection [13], ShH10 exhibits a newly
conferred HSPG dependence, allowing it to better bind and
traverse the ILM (Fig. 6b). Preliminary results indicate that the
D532N mutation (shown in green in Fig. 7a) may be responsible
for this dependence, as the D532N mutant exhibits enhanced viral
binding to heparin and significantly increased transduction of
CHO cells (data not shown and Fig. 6a, S2). This mutation lies
next to the K531 residue (shown in purple in Fig. 7a) that has
been shown to confer heparin binding to wild-type AAV6 [35].
The loss of negative charge in the D532N mutant may facilitate
more efficient electrostatic interactions between K531 and the
negatively charged sulfate groups present within HSPG. AAV2’s
higher HSPG affinity, but lower transduction efficiency, relative to
ShH10’s (Fig. S2) may then suggest a potential dueling role in
achieving optimum transduction, as too high of an affinity may
also encumber efficient viral penetration in the retina.
Once it traverses the ILM, ShH10 must bind Mu¨ller cells.
Recent studies have implicated the epidermal growth factor
receptor (EGFR), which is expressed on the surface of Mu¨ller cells,
as a coreceptor for AAV6 transduction [42,43]. However, since
AAV6 is largely refractory to intravitreal transduction and has a
marginal ability to transduce Mu¨ller cells subretinally [14],
Figure 5. Retinal astrocyte infectivity of ShH10. Fundus imaging of rShH10 dsCAG-GFP injected animals at one week (A) reveals a characteristic
expression pattern localized near major vasculature and the optic nerve, which subsequently shows spreading after three weeks (B). Closer
examination by flatmount (C) through laminin (red) and DAPI (blue) staining reveals a strong localization of GFP expression along the edges of retinal
blood vessels, areas dense in retinal astrocytes. Transverse sections (D) stained for calbindin (red), a marker of RGCs and interneurons in the retina,
illustrate a local region of expression within retinal astrocytes and Mu¨ller cells ensheathing a blood vessel.
doi:10.1371/journal.pone.0007467.g005
Mu¨ller-Permissive AAV Variant
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ShH10’s novel tropism may then partly result from an improved
binding affinity for EGFR (or another co-receptor) to enable
Mu¨ller cell binding and endocytosis.
Preliminary results suggest that the N451D mutation may partly
be responsible for such potentially improved receptor interactions,
as this substitution is sufficient to confer a limited Mu¨ller cell
intravitreal infectivity (Fig. 7). The asparagine to aspartic acid
mutation places a negative charge near the tip of the 3-fold axis of
symmetry on the AAV capsid (Fig. 7a), an area implicated in
receptor binding on the AAV2 capsid [5]. Intriguingly, the N451D
mutation (shown in blue in Fig. 7a) alone decreased viral
transduction of CHO and Pro5 cells (Fig. 6), but when this
mutation is combined with the D532N change, viral transduction
of CHO cells is synergistically improved. This synergism may then
reflect an improved receptor/co-receptor relationship, with the
D532N mutation negating the detrimental aspects of the N451D
mutation while concomitantly enhancing binding to a primary
proteoglycan receptor (i.e. HSPG).
ShH10 exhibited enhanced transduction of Mu¨ller cells
underlying areas of retinal vasculature, suggesting that its
infectivity of retinal astrocytes may also offer a possible
mechanistic explanation for its tropism. Whether this is just a
result of commonalities between these glial subtypes that allow for
ShH10 permissivity in both or whether infection of one type may
facilitate adjacent infection of the other through localized binding
remains to be analyzed. Regardless, this property would be useful
in infecting the activated Mu¨ller cells in neovascularized tissue to
deliver neurotrophic factors to sites of vascular abnormalities [29].
Overall, efficient and selective intravitreal transduction of
Mu¨ller cells by AAV may provide safer and more effective
Figure 6. In vitro characterization of ShH10. (A) CHO cell transduction by rAAV6, rAAV6 N451D, rAAV6 D532N, and rAAV6 N451D+D532N
carrying CMV-GFP. (B) CHO/PgsA transduction demonstrating the HSPG dependence of various permutations of the mutations that comprise ShH10.
(C) Pro5/Lec1 transduction examining sialic acid dependence of various permutations of the mutations that compose ShH10.
doi:10.1371/journal.pone.0007467.g006
Mu¨ller-Permissive AAV Variant
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treatments for retinal degenerative conditions through secretion of
neuroprotective factors, while also enabling basic investigations to
gain a greater understanding of Mu¨ller cell physiology. For
instance, the uncertain role of Mu¨ller cells in the visual cycle of
cone photoreceptors can be examined in vivo through Mu¨ller-
specific AAV-mediated RNAi-knockdown of factors implicated in
11-cis-retinol generation [44]. Likewise, in a similar approach, the
undefined role of these cells in regulating the fluid dynamics of the
retina could be further explored by specifically modulating Mu¨ller
aquaporin (AQP) levels [45].
For future studies, the use of highly diverse AAV libraries
coupled with in vivo selections could provide a more powerful
approach to directly target specific cell types in the retina. For
example, the targeting of engineered light gated channels to
specific subpopulations of retinal cells, such as ON bipolar cells or
ON/OFF retinal ganglion cells [46], may restore functional vision
in individuals with a severely degenerated ONL by reestablishing
downstream retinal circuitry. Likewise, targeted delivery to
photoreceptors may enable additional strategies for neuroprotec-
tive therapy.
Methods
Generation of rAAV vectors
Vectors were produced by the plasmid co-transfection method
[14], and the resulting lysates were purified via iodixanol gradient
ultracentrifugation as previously described [31]. This fraction was
then passed through a heparin column, which was washed with
5 mL PBS and eluted with 5 mL of a 1 M NaCl solution. The
resulting viral fractions were desalted and concentrated with
Amicon Ultra-15 Centrifugal Filter Units to a final volume of
200 ml. Vector was then titered for DNase-resistant vector
genomes by real time PCR relative to a standard.
Intraocular administration routes
Adult wild type Spaque Dawley rats were used for all studies. All
animal procedures were conducted according to the ARVO
Statement for the Use of Animals and the guidelines of the Office
of Laboratory Animal Care at the University of California,
Berkeley. Before vector administration, rats were anesthetized with
ketamine (72 mg/kg) and xylazine (64 mg/kg) by intraperitoneal
injection. An ultrafine 30 1/2-gauge disposable needle was passed
through the sclera, at the equator and next to the limbus, into the
vitreous cavity. Injection of 5 ml, containing 12561012 vg/ml of
AAV dsCAG-GFP, was made with direct observation of the
needle in the center of the vitreous cavity.
Fundus photography
Fundus imaging was performed one to eight weeks after
injection with a fundus camera (Retcam II; Clarity Medical
Systems Inc., Pleasanton, CA) equipped with a wide angle 130u
retinopathy of prematurity (ROP) lens to monitor eGFP
expression in live, anesthetized rats. Pupils were dilated for fundus
imaging with phenylephrine (2.5%) and atropine sulfate (1%).
Cryosections
One to eight weeks after vector injection, rats were humanely
euthanized, the eyes were enucleated, a hole was introduced in the
cornea, and tissue was fixed with 10% neutral buffered formalin
for 2–3 hours. The cornea and lens were removed. The eyecups
were washed in PBS followed by 30% sucrose in the same buffer
overnight. Eyes were then embedded in optimal cutting temper-
ature embedding compound (OCT; Miles Diagnostics, Elkhart,
IN) and oriented for 10 mm thick transverse retinal sections.
Immunolabeling and histological analysis
Tissue sections were rehydrated in PBS for 5 min, followed by
incubation in a blocking solution of 1% BSA, 0.5% Triton X-100,
and 2% normal donkey serum in PBS for 2–3 hours. Slides were
then incubated with commercial monoclonal antibodies raised
against glutamine synethetase in rabbit (Sigma G2781) at a 1:3000
dilution, calbindin (Abcam ab11426-50) in rabbit at a 1:1000
dilution, vimentin in mouse (Dako M0725) at a 1:1000 dilution, or
laminin in rabbit (Sigma, L9393) at 1:100 in blocking solution,
overnight at 4uC.
The sections were then incubated with Cy3-conjugated
secondary anti-rabbit or anti-mouse antibody (Molecular Probes)
at a 1:1000 dilution in blocking solution for 2 hours at room
temperature. The results were examined by fluorescence micros-
copy using an Axiophot microscope (Zeiss, Thornwood, NY)
equipped with a Xcite PC200 light source and QCapturePro
camera or a confocal microscope (LSM5; Carl Zeiss Microima-
Figure 7. rAAV6 N451D expression following intravitreal injection. Confocal imaging of immunostained transverse retinal sections 3 weeks
post-injection of rAAV6 N451D dsCAG-GFP (B, C). GFP expression analysis (B) and overlay with GS (C) reveal this mutant to be sufficient for an
intravitreal Mu¨ller infection, though at a reduced efficiency relative to ShH10 (fig. 1D, F). Mapping of this mutation onto the AAV6 capsid subunit VP3
(A) (blue) shows its location near the three-fold axis of symmetry of the assembled capsid. Three-dimensional models of the AAV6 VP3 subunit were
generated using Swiss Model with the coordinates of AAV2 (Protein Databank accession no. 1LP3) supplied as a template and images were rendered
in Pymol and Rasmol. Additionally, the D532N mutation (green) maps near the HSPG-binding domain (purple) [35].
doi:10.1371/journal.pone.0007467.g007
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ging). Transduction profiles were analyzed by counting individual
cells from whole retinas in 15 mm cryosections (n = 6) using
fluorescence microscopy. Efficiencies were calculated by dividing
the total number of these transduced Mu¨ller cells by the total
number of Mu¨ller cells in the retinal slice (mm) in which these cells
were present (n = 6).
In Vitro Transduction Analysis
Transduction studies using rAAV CMV-GFP were performed
with 56104 cells (CHO, pgsA, Pro5, and Lec1) in 12-well plates.
Cells were transduced with rAAV GFP vectors at a gMOI of 103–
105 (n = 3), and the percentage of GFP-expressing cells was
determined by flow cytometry 48 hours post-infection.
Supporting Information
Figure S1 Sequence analysis of novel AAV variants. Sequence
comparison between ShH10 and ShH13 along with parent AAV
serotypes 2 and 6.
Found at: doi:10.1371/journal.pone.0007467.s001 (0.03 MB
PDF)
Figure S2 Heparin binding affinity of ShH10, AAV2, and
AAV6. Elution profile from a heparin column for ShH10, AAV2,
and AAV6. Y-axis values represent the fraction of virus eluted, and
the X-axis represents the concentration of NaCl in the eluant
(mM).
Found at: doi:10.1371/journal.pone.0007467.s002 (8.32 MB TIF)
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